Prolastin c 1,000 MG/20 ML VLS
Ended Awarded Last action
- Contract number
- SPE2DR26FQLP7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,230
Award facts
- Contract value 100% obligated
- $10,230.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,230 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on January 27, 2026, with an ultimate completion date of February 18, 2026, was awarded without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded in November 2025 that positions the company as a critical regional pharmaceutical supplier for Department of Defense medical operations.
DMS Pharmaceutical Group has demonstrated substantial federal contracting activity as a prime vendor under the PPV-G GEN V framework, which is part of the broader $30.3 billion Defense Logistics Agency acquisition strategy to ensure consistent pharmaceutical supply to military healthcare facilities worldwide. The company supplies a comprehensive range of pharmaceutical products including branded and generic medications, biologics, vaccines, and specialty pharmaceuticals to support recurring medical supply needs across the Department of Defense. With no identified subcontractors and consistent performance on multiple delivery orders ranging significantly in value, DMS Pharmaceutical Group serves as an essential pharmaceutical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQLP7?
SPE2DR26FQLP7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FQLP7 worth?
The government has obligated $10,230 on SPE2DR26FQLP7.
Is contract SPE2DR26FQLP7 an order under another contract?
Yes. SPE2DR26FQLP7 is a delivery order under SPE2DR25D9354, an indefinite delivery contract.
Was contract SPE2DR26FQLP7 competed?
The extent of competition for SPE2DR26FQLP7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award